The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML.
Given the recent advances in the treatment of hematologic malignancies and the many other treatments on the horizon, physicians and payers will be faced with the critical decisions of when to use new treatments in the clinical pathway and how to allocate healthcare resources. This review will provide an overall context for the clinical, economic and quality of life burden of leukemia, as well as provide cross-analysis among the four major types of leukemia: acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia.
Redaelli
Alberto
A
Pharmacia Corporation, Milan, Italy. alberto.redaelli@pharmacia.com
Stephens
Jennifer M
JM
Laskin
Benjamin L
BL
Pashos
Chris L
CL
Botteman
Marc F
MF
D000818:Animals; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000453:epidemiology* / Q000523:psychology / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D007951:Leukemia, Myeloid / Q000453:epidemiology* / Q000523:psychology / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D011788:Quality of Life / Q000523:psychology; D016896:Treatment Outcome